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Introduction
Th e circadian rhythm is generated by a central circadian 
oscillator in the suprachiasmatic nucleus of the hypo-
thala mus [1]. Th is nucleus has many connections to other 
centers in the brain. Th e circadian activity of this 
particular nucleus is transferred to the immune system 
via the hypothalamic hypothalamic–pituitary–adrenal 
(HPA) axis, leading to the typical undulation of clinical 
symptoms in chronic inﬂ ammatory diseases with a 
maximum in the early morning hours [2]. In this review 
we will describe circadian rhythms in rheumatoid 
arthritis (RA) and other rheumatic and chronic inﬂ am-
matory diseases, dysfunction of the HPA axis in RA and 
other rheumatic and chronic inﬂ ammatory diseases, the 
problem of adrenal suppression by glucocorticoid (GC) 
therapy, and whether or not chronotherapy with pred ni-
sone is more eﬀ ective and aggravates adrenal suppression.
Circadian rhythms in RA and other chronic 
infl ammatory diseases
Classical symptoms of RA, such as morning stiﬀ ness and 
swelling, show a clear temporal relationship with 
nocturnally elevated levels of proinﬂ ammatory cytokines, 
as a consequence of a cascade of increased nocturnal 
inﬂ ammation [3]. Several of these cytokines, such as 
tumor necrosis factor (TNF) alpha and interleukin (IL)-6, 
are highly increased in patients with active RA in the 
early hours of the day, but are found at very low levels 
after noon [4]. Th eir release pattern and serum concen-
trations, possibly triggered by proinﬂ ammatory hormones 
such as melatonin (and prolactin), follow a 24-hour daily 
cycle [5]. Also, the cortisol rhythm  – which is also 
present in healthy individuals, and therefore is primary, 
with low levels at night – may explain nocturnal inﬂ am-
mation. Since cortisol is the strongest endogenous anti-
inﬂ ammatory substance, its downregulation during the 
evening and night is linked to an increase of inﬂ ammation 
during the early morning, and its upregulation in the 
early morning is most probably related to inhibition of 
inﬂ ammation during the day [1]. Th e early morning in-
ﬂ am matory signs, typical for many inﬂ ammatory rheu-
matic conditions, can thus be explained.
As noted, the proinﬂ ammatory hormones begin to rise 
before the daily early morning aggravation of RA symp-
toms, and before activation of endogenous cortisol 
synthesis that counteracts the cascade of the immune/
inﬂ ammatory processes [3]. In addition, rhythmic ﬂ uctu-
ations of the nocturnal secretion and the peripheral 
metabolism of endogenous cortisol, as well as changes in 
the activation of biologically inactive to active cortisone 
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in the synovial cells (intracrinology), appear important in 
the pathophysiology of RA [6].
Th e RA inﬂ ammatory process therefore induces changes 
in synovial ﬂ uid composition, edema of synovial tissue, as 
well as redistribution of interstitial ﬂ uid, while sleeping 
contributes to clinical stiﬀ ness of the joints that is most 
pronounced in the early morning [7]. All of these processes 
are closely linked to regulatory interactions between the 
endocrine, nervous and immune systems, with distinct 
24-hour daily rhythms (neuroendocrine immunology).
While the role of IL-6 and TNF alpha in the regulation 
of inﬂ ammatory and immune responses, particularly in 
RA, is well established, the increased production of other 
proinﬂ ammatory cytokines such as IL-8, IL-12 and IL-17 
by primary and secondary immune cells may also be 
implicated in the circadian process [7]. Furthermore, in 
polymyalgia rheumatica (PMR), symptoms of pain and 
stiﬀ ness typically are most prominent during the early 
morning, similar to RA [2]. Th ere are indications for 
circadian variation of TNF alpha and IL-6 secretion, with 
peak values in the early morning hours. Th erefore, given 
the known high GC sensitivity of PMR, time-adapted GC 
therapy can be hypothesized to probably be more 
eﬀ ective than the currently used standard regimen in 
improving clinical symptoms [8-10].
Of note, in ankylosing spondylitis – another inﬂ am ma-
tory arthritic condition – pain and stiﬀ ness also seem to 
be most prominent during the early morning hours [2]. 
Finally, it is now also evident that symptoms of diseases 
such as RA, which is T  helper  1 dependent, but also 
asthma, which is T helper 2 dependent, are inﬂ uenced by 
diurnal rhythms and natural regulatory T cells [11]. In 
particular, secretion of IL-2, interferon gamma and IL-10 
by naïve CD4+ T cells follows a diurnal rhythm.
Dysfunction of the HPA axis in RA and other 
chronic infl ammatory diseases
From a GC perspective, the general problem of RA and 
other inﬂ ammatory diseases is that serum cortisol 
concentrations are inadequately low relative to inﬂ am-
mation [12,13]. What exactly does this mean?
Infl ammatory stress activates the HPA axis
In a fairly heroic study in 18 healthy young men, either 
saline or low or high doses of recombinant human IL-6 
were infused into one femoral artery for 3  hours [14]. 
Subjects experienced clinical symptoms such as shivering 
and discomfort during high-dose IL-6 administration, 
but were asymptomatic during low-dose IL-6 adminis tra-
tion. Plasma cortisol concentrations did not change 
during infusion of saline but markedly increased during 
both high and low doses of IL-6. While concentrations of 
plasma cortisol declined after 2 hours of infusion in low 
doses of IL-6, they remained elevated in high doses of 
IL-6 at 3  hours of infusion. During both IL-6 trials, 
plasma cortisol levels returned to preinfusion values after 
3 hours of recovery [14].
Th e increase of cortisol levels in reaction to IL-6 
infusion is provoked by activation of the HPA axis 
(Figure 1A). Remarkably, the relation between IL-6 levels 
and the adrenocorticotropic hormone (ACTH)/cortisol 
levels is linear. In a study of 15 healthy young men in 
which recombinant IL-6 was applied subcutaneously, 
plasma ACTH concentrations and plasma cortisol levels 
increased dose dependently, and the ratio of hormone to 
IL-6 serum levels was constant [15].
However, repeated IL-6 administration leads to adap ta-
tion of the HPA response. During a phase I trial, patients 
with cancer and a good performance status received daily 
morning subcutaneous injections of 30  μg/kg IL-6 for 
7 consecutive days. IL-6 caused impressively marked and 
prolonged elevations of plasma ACTH and cortisol on 
the ﬁ rst day, but blunted ACTH responses on the seventh 
day of treatment, perhaps as a result of increased baseline 
cortisol levels [16].
Inadequate cortisol secretion in relation to infl ammation
In chronic inﬂ ammation, cortisol secretion appears to be 
inadequate in relation to inﬂ ammation. In a retrospective 
study with 34 patients with RA, 46 patients with reactive 
arthritis and 112 healthy subjects, the authors measured 
serum levels of IL-6, TNF and cortisol. Th e absolute 
levels of IL-6 were lower in healthy controls than in 
reactive arthritis and RA patients. However, the ratio of 
serum cortisol to serum cytokines was much higher in 
healthy controls than in reactive arthritis and RA 
patients, due to similar cortisol levels in all groups [13].
In a study by Croﬀ ord and colleagues comparing the 
circadian course of ACTH and cortisol levels in patients 
with RA and in healthy subjects, despite 10 times higher 
serum levels of cytokines in patients with RA, serum 
level curves of ACTH and cortisol were identical, with 
similar peaks in the early morning and lower second 
peaks in the afternoon [12]. Th e ACTH/cortisol hormone 
secretion in patients with RA is thus inadequate in 
relation to inﬂ ammation. Th is inadequacy is one reason – 
apart from their pharmacological eﬀ ects – why low-dose 
GCs represent such an important part of modern RA 
therapy [17]. Data from the German registry show that 
GCs had been used in 55% of patients with RA in 1996 
and were still used in 55% of patients with RA in 2010, 
even if the frequency of patients using low-dose therapy 
≤7.5  mg prednisone equivalent increased from 40% to 
48% [18].
Dysfunction of the HPA axis can also be found in PMR/
giant cell arteritis. In a study comparing serum values of 
ACTH, cortisol and CRP in patients with PMR/giant cell 
arteritis and controls, ACTH and cortisol levels were not 
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Figure 1. Function and dysfunction of the hypothalamic–pituitary–adrenal axis in infl ammation. (A) Activation of the hypothalamic–
pituitary–adrenal (HPA) axis and negative feedback regulation. The central circadian oscillator and diff erent stressors (physical, emotional, fever, 
hypoglycemia, or hypotension) during physiological stress reactions trigger the hypothalamus to release corticotropin-releasing hormone (CRH). 
CRH acts on the anterior pituitary and induces release of adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal gland to 
produce and release cortisol. Cortisol exhibits its known metabolic eff ects (mainly provision of glucose and energy), which serve to counteract 
the stressor. Infl ammation can also trigger the HPA axis. In the physiological regulation of the HPA axis, cortisol release is terminated by negative 
feedback regulation of cortisol on the hypothalamus and anterior pituitary. Synthetic glucocorticoids (GCs) applied in GC therapy can cause 
negative feedback regulation. This can lead to adrenal suppression. (B) A new concept for the feedback loop: the hepato-hypothalamic–pituitary–
adrenal–renal axis. The HPA axis is extended by GC metabolism: cortisol is converted to cortisone mainly by the kidney, via 11β-hydroxysteroid 
dehydrogenase (11β-HSD) type 2, in order to protect the nonspecifi c mineralocorticoid receptor from activation by cortisol. The major organ for 
converting cortisone to cortisol is the liver, via 11β-HSD1. In chronic infl ammation, conversion from cortisone to cortisol by 11β-HSD1 is increased 
(reviewed in [20]). This may amplify negative feedback and explain HPA dysfunction in infl ammation. SERVIER medical art images were used for 
generation of fi gures.
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diﬀ erent in patients with PMR/giant cell arteritis and 
controls, whereas the ratios of serum ACTH/serum CRP 
and serum cortisol/serum CRP were signiﬁ cantly lower 
in PMR/giant cell arteritis patients than in healthy 
controls [19]. Th us, in PMR/giant cell arteritis there also 
appears to be an inadequate cortisol secretion in relation 
to inﬂ ammation in terms of relative adrenal insuﬃ  ciency. 
GC therapy can be regarded  – at least in part  – as 
supplemental GC therapy, supported by the high GC 
sensitivity in these diseases [4].
New concept for the feedback loop: 
the hepato-hypothalamic–pituitary–adrenal–renal axis
How may the dysfunction of the HPA axis in chronic 
inﬂ ammation be induced? Recently, evidence has accu-
mu lated, been reviewed and presented as a concept that 
dysfunction of the HPA axis in chronic inﬂ ammation is 
not simply an adaptation to chronic stress, but may be 
due to increased negative feedback of active cortisol on 
the HPA axis [20].
Th e HPA axis has been recognized to be extendable to 
a hepato-hypothalamic–pituitary–adrenal–renal axis by 
GC metabolism. Active cortisol is converted to inactive 
cortisone mainly by the kidney, via 11β-hydroxysteroid 
dehydrogenase (11β-HSD) type 2, in order to protect the 
nonspeciﬁ c mineralocorticoid receptor from activation 
by cortisol. On the other hand, the major organ for 
converting inactive cortisone to active cortisol is the liver, 
via 11β-HSD1 (Figure 1B).
Expression of 11β-HSD1 is markedly enhanced by TNF 
and proinﬂ ammatory cytokines [20]. Th e liver therefore 
becomes an important player in systemic inﬂ ammation, 
even if the conversion also occurs in multiple other 
tissues including the brain, adipocytes, vascular cells, 
osteoblasts and ﬁ broblasts. Given the role of the 11β-
HSD1 in GC metabolism, its eﬀ ect on the HPA axis and 
its interaction with inﬂ ammatory cytokines, it is hypo-
the sized that in chronic inﬂ ammatory diseases, cytokine-
induced increased expression of 11β-HSD1 induces a 
change in the HPA axis [20]. Increased negative feedback 
of active cortisol on the HPA axis induced during 
inﬂ ammation may thus be the mechanism of dysfunction 
of the HPA axis in chronic inﬂ ammation (Figure 1B).
Adrenal suppression by glucocorticoid therapy
Tertiary adrenal insuffi  ciency induced by glucocorticoid 
therapy
During the physiological regulation of the HPA axis, 
cortisol release is terminated by negative feedback 
regulation of cortisol on the hypothalamus and anterior 
pituitary (Figure 1A). Also, synthetic GCs – as applied in 
GC therapy  – can cause negative feedback regulation, 
leading to adrenal suppression in terms of tertiary 
adrenal insuﬃ  ciency [21].
Tertiary adrenal insuﬃ  ciency typically becomes 
manifest in patients treated long term with synthetic GCs 
during situations of stress; for example, infections or 
operations [22]. Tertiary adrenal insuﬃ  ciency generally 
has a less dramatic presentation than primary adrenal 
insuﬃ  ciency; acute circulatory collapse seems rare, 
because aldosterone levels, which are controlled pre-
dominantly by the renin–angiotensin system, are 
preserved [21]. GC-treated patients may be identiﬁ ed by 
symptoms of Cushing’s syndrome [22].
Diagnosis of tertiary adrenal insuffi  ciency
Th e diagnosis of tertiary GC-induced adrenal insuﬃ  -
ciency is based on the patient’s history (therapy with 
GCs), low plasma cortisol and ACTH levels near zero, 
and functional tests such as the corticotropin-releasing 
hormone (CRH) or ACTH stimulation test. Th e CRH test 
allows testing of the adrenal partial function of the 
anterior pituitary. In principle, CRH injection induces 
cortisol secretion (via ACTH). In practice, 100  μg CRH 
are injected intravenously, and blood samples are 
acquired 0, 60, 90, and 120  minutes after injection for 
analysis of ACTH and cortisol plasma concentrations. 
Th e CRH test can be interpreted as normal with ACTH 
increase >50% and cortisol increase >5 μg/dl. In tertiary 
adrenal insuﬃ  ciency (and adrenal Cushing’s syndrome), 
no increase can be measured (whereas in central 
Cushing’s syndrome, exaggerated increase can be found).
Th e ACTH test allows testing of primary and tertiary 
adrenal insuﬃ  ciency. In the test, 250  μg ACTH are 
injected intravenously and blood samples are acquired 0, 
60, and 120 minutes after injection for analysis of cortisol 
plasma concentrations. Increases of cortisol >10  μg/dl 
(276 nmol/l) would be normal [22].
Factors that determine adrenal insuffi  ciency
As is well known, occurrence of GC-induced tertiary 
adrenal insuﬃ  ciency is dependent on diﬀ erent factors: 
individual sensitivity, GC dose, duration and preparation 
of GC therapy, and timing of application (circadian).
Individual sensitivity
Th e inﬂ uence of individual factors on adrenal suppression 
is not yet well understood. In a study in RA patients and 
controls, 1.5  mg dexamethasone was given orally at 
11:00  p.m., which was followed by application of CRH 
intravenously at 3:00  p.m. on the following day [23]. 
Normal controls and a number of the patients showed a 
suppression of ACTH and cortisol response as expected. 
However, three of seven patients (43%) with active RA 
(without GC therapy) did not exhibit the normal 
feedback control mechanism. Th is suggests that there 
might be a subpopulation of patients with RA who have 
impaired GC feedback [23].
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In a study investigating the adrenal response after 
stopping GC treatment, a CRH test was performed in 75 
patients who had received at least 25 mg prednisone daily 
for up to 30 days [24]. Interestingly, about one-half of the 
patients (34 of 75 patients) again showed a reduced 
response to CRH on the day after stopping treatment.
Glucocorticoid dose
Th e frequency of adrenal suppression increases with 
increasing GC dosages. In arthritis and asthma patients 
treated with prednisone equivalent doses ranging from 5 
to 20 mg, cortisol response in the ACTH test was normal 
(that is, cortisol rise ≥7 μg/dl) in all of the patients taking 
a single morning dose of 5 to 7.5  mg prednisone, was 
blunted (that is, cortisol rise <7 μg/dl) in 33% and 47% of 
the patients taking 10 to 12.5 mg and 15 mg prednisone, 
respectively, and was suppressed (no rise) in 44% of the 
patients taking 20 mg prednisone [25].
Evidence that low-dose GC therapy can also result in 
adrenal suppression was found in a more recent 
randomized, double-blind and placebo-controlled trial in 
patients with RA investigating the plasma cortisol 
response in ACTH testing before and after 12  weeks of 
treatment with 7.5 mg prednisolone [26]. After 12 weeks 
of 7.5  mg prednisolone, the mean values for the 
60-minute response to ACTH were reduced by 35%. 
Following treatment, 46% of patients taking 7.5  mg 
prednisolone failed to reach the normal maximum cortisol 
response to ACTH, even if the HPA axis response 
generally remained within the normal range [26].
Duration and preparation of glucocorticoid therapy
Abnormal diurnal rhythms of plasma cortisol in patients 
with RA were found to be related to the total dose of 
GC given and to the duration of therapy, but not to the 
mean daily dose or the daily regimen of therapy [27]. 
Patients receiving triamcinolone, dexamethasone and 
betametha sone had a higher prevalence of abnormal 
diurnal rhythm of plasma cortisol when compared with 
patients receiving prednisone or prednisolone, or 
methylprednisolone. Th e signiﬁ cance of this ﬁ nding is 
uncertain since patients receiving the former group of 
drugs had received their GC therapy in higher dosage 
and for longer duration [27].
Circadian application
In the 1960s several studies conﬁ rmed that splitting the 
daily dose into several divided doses strongly increases 
the risk of adrenal suppression. For example, whereas 
endogenous cortisol secretion was not altered with a 
single dose of 8  mg tri amcinolone given at 8:00  a.m., 
application of four divided 2 mg doses resulted in marked 
suppression of cortisol levels [28]. Th is is the reason why 
GC therapy in general is applied as a single daily dose.
Th e time point of application of the single daily dose 
also plays a role for adrenal suppression. Th is can be 
explained easily: circadian GC secretion exhibits two 
peaks, one large peak in the morning around 8:00  a.m. 
and a smaller peak in the afternoon around 2:00  p.m. 
[12]. Of note, cortisol levels are high during the ﬁ rst peak 
in the morning, causing downregulation of ACTH levels 
via negative feedback regulation. In consequence, cortisol 
secretion is also downregulated. At a certain point, 
reduced cortisol levels cause upregulation of ACTH 
again, leading in turn also to upregulation of cortisol 
secretion during the second peak in the afternoon. If 
exogenous GCs were applied in the evening, the so-called 
quiet period for the adrenal gland [29], this would cause a 
negative signal on ACTH and therefore also cortisol 
secretion in the morning.
Th is has been demonstrated in several experimental 
studies in healthy persons: 4-hour methylprednisolone 
infusion (0.7 mg/hour) between midnight and 4:00 a.m. 
induced severe adrenal suppression, whereas 4-hour 
infusion between 4:00 and 8:00 a.m. or between 4:00 and 
8:00  p.m. induced moderate adrenal suppression. In 
contrast, 8-hour infusion (twice the methylprednisolone 
dose delivered in the other clock-hour trials) between 
8:00  a.m. and 4:00  p.m. exerted no adrenal suppression 
[29,30]. Dexamethasone 0.5 mg administered at 8:00 a.m. 
or 4:00  p.m. caused only temporary suppression of 
cortisol secretion, whereas the same amount given at 
midnight produced virtually complete suppression of 
cortisol production for a full 24-hour period [31]. For this 
reason, GC therapy in general is applied in a single 
morning dose, as ﬁ rst recommended by Di Raimondo 
and Forsham in 1956 [32,33].
Dose splitting
Th is approach of choosing the right time for GC application 
primarily focused on chronotoxicological aspects; that is, 
rhythm-dependent diﬀ erences in the manifestation and 
severity of adverse eﬀ ects. However, despite the practice of 
the single morning dose, some patients receiving GC 
therapy for RA required a nocturnal GC dose to control 
morning stiﬀ ness [34]. Th is brought chronoeﬀ ectiveness 
into focus; that is, rhythm-dependent diﬀ erences in the 
magnitude of the desired therapeutic eﬀ ects [35].
Th e question is whether dose splitting into a morning 
and an evening dose is adequate for chronotherapy. Th ere 
are reports showing no evidence of HPA suppression in 
any of the patients who received a low single daily dose of 
GC treatment, even when the dose was given at bedtime 
[25,36,37]. In contrast, dose splitting with morning and 
evening doses appears to cause more HPA suppression; 
in seven patients who were receiving prednisolone twice 
daily in a similar total daily dose as compared with these 
single daily dose experi ments, three patients showed 
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HPA suppression and two patients had lost growth 
hormone responsiveness [36]. However, splitting is 
necessary in some patients, so when is the best time for 
dose splitting? Th ere is evidence from a French study 
using dutimelan 8-15  mite  – a GC preparation with a 
morning (8:00  a.m., Dragee A: 3.5  mg prednisolone 
acetate  + 2  mg prednisolone alcohol) and an afternoon 
(3:00  p.m., Dragee B: 1.5  mg prednisolone alcohol  + 
7.5 mg cortisone acetate) application – that the morning 
peak of endogenous cortisol secretion was preserved 
[38]. It can be concluded that, if dose splitting is 
necessary, exogenous GCs should be applied in the 
morning and early afternoon (3:00 p.m.) (2/3 + 1/3 dose).
Does modifi ed-release prednisone aggravate 
adrenal suppression?
Chronotherapy with modifi ed-release prednisone
From the pharmacokinetic standpoint there is no reason 
why prednisolone should be given at any particular time 
of day or night, as prednisolone pharmacokinetics does 
not show a diurnal rhythmicity [39]. However, treatment 
in the early afternoon or evening may be not be suﬃ  cient 
to dampen the response in the early morning, due to the 
short half-life of prednisolone (2 hours) and the intense 
immune activation during the night [1,39,40].
Several studies had suggested a greater eﬀ ect of 
bedtime or night doses (2:00  a.m.) in comparison with 
morning doses of conventional prednisone on morning 
stiﬀ ness [34,41-43]. However, a regimen that requires 
regular waking of the patient at 2:00 a.m. was considered 
impractical for the therapeutic routine. Other studies had 
found no diﬀ erences [44,45], and the inﬂ uence on the 
HPA axis was not examined in these studies [34,41-45].
Th ese considerations and observations led to the 
development of a new modiﬁ ed-release (MR) prednisone 
tablet formulation [46]. MR prednisone releases pred-
nisone approximately 4 hours after ingestion; that is, at 
approximately 2:00  a.m. if taken at 10:00  p.m. bedtime. 
Th e CAPRA-1 study was a double-blind treatment with 
MR prednisone in comparison with morning adminis-
tration of immediate-release prednisone for 12  weeks, 
followed by 9-month open-label extension treatment 
with MR prednisone (total duration of study 12 months) 
[46,47]. MR prednisone produced a clinically relevant 
reduction of morning stiﬀ ness of the joints in addition to 
all known therapeutic eﬀ ects of immediate-release 
prednisone. In the open-label extension treatment, 
sustained reduction in morning stiﬀ ness was found in the 
MR prednisone-treated group.
CAPRA-1 subgroup study with corticotropin-releasing 
hormone tests
Th ese results lead to the question of whether chrono-
therapy with MR prednisone aﬀ ects adrenal suppression. 
Th e inﬂ uence of long-term, low-dose chronotherapy with 
MR prednisone on the HPA axis was investigated by 
CRH tests in a subgroup of 28 patients in the CAPRA-1 
study [48]. Th e CRH tests were performed at baseline, at 
the end of the double-blind phase, and at the end of the 
9-month open-label extension. Sixty-two valid tests were 
obtained in 28 patients.
Th ere were no measurable diﬀ erences in mean cortisol 
changes after CRH injection between baseline and the 
end of the study [48]. Furthermore, there was no 
indication that changing treatments from immediate-
release prednisone to MR prednisone increased the risk 
of HPA axis insuﬃ  ciency, or resulted in deterioration of 
preexisting suppression. Fifty percent of the patients 
showed a normal response (change ≥5 μg/dl) in the CRH 
test in immediate-release and MR prednisone treatment 
groups, 37.5% and 36.7%, respectively, of the patients 
showed suppressed response (change >0 to <5 μg/dl), and 
12.5% and 13.3%, respectively, of the patients showed no 
response (no change). Th ere was thus no diﬀ erence 
between immediate-release prednisone and MR pred-
nisone in numbers of normal/suppressed/no response 
reactions. In addition, no adverse events that could be 
attributed to HPA axis insuﬃ  ciency were observed 
during treatment with low-dose MR prednisone for the 
entire treatment period of 12 months [48].
Eff ect of modifi ed-release prednisone on cortisol levels
A recent study showed an increase of endogenous 
cortisol after 2 weeks of MR prednisone therapy in 
patients with active RA who had received no GCs by any 
route in the preceding 3  months [49]. MR prednisone 
released at 2:00  a.m. suppressed the pathological early 
morning rise in plasma IL-6 in RA. Th e nocturnal rise in 
plasma cortisol was not suppressed but was enhanced 
with a peak value increase from 14.1 to 19.3  μg/dl, 
consistent with a changing relationship between HPA 
axis and immune system activation [49]. Th is observation 
may be an indication that the HPA axis is preserved and 
is activated even more during MR prednisone treatment 
compared with pre-MR prednisone treatment.
Conclusions
From a GC perspective, circadian rhythms of the HPA 
axis and connected subsystems, including the immune 
system, appear to be essential for understanding of 
patho physiology and treatment in rheumatology. Th e 
circadian rhythm of the HPA axis in chronic inﬂ am-
matory diseases may be defective in terms of not bringing 
the body into a position to overcome the signs and 
symptoms of the disease. GC therapy serves as a 
necessary aid to overcome the disease and perhaps 
restore the deranged circadian rhythm. In a number of 
patients (around 50%), GC therapy causes adrenal 
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suppression, probably mainly due to as yet undeﬁ ned 
individual factors (apart from dose, substance and 
duration of therapy). In order not to aggravate adrenal 
suppression, GC therapy should be applied in accordance 
with the circadian rhythm, to achieve greatest eﬃ  cacy 
along with highest safety. It has been suggested that when 
the single morning dose is not eﬀ ective enough to achieve 
suﬃ  cient disease control, especially in patients with 
strong night symptoms and morning stiﬀ ness, split doses 
in the morning and afternoon, or chronotherapy with 
MR prednisone, can to some extent avoid aggravation of 
adrenal suppression.
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